# EDGAR Filing Document

**Accession Number:** 0001827639
**File Stem:** 0001104659-25-115098
**Filing Date:** 2025-11
**Character Count:** 9226
**Document Hash:** a2ac6ef6e6d20e66e463b9780b48034e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-115098.hdr.sgml**: 20251121

**ACCESSION NUMBER**: 0001104659-25-115098

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251120

**FILED AS OF DATE**: 20251121

**DATE AS OF CHANGE**: 20251121

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Mastrocola Lauren
- **CENTRAL INDEX KEY:** 0001827639

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39620
- **FILM NUMBER:** 251509436

**MAIL ADDRESS:**
- **STREET 1:** C/O PRAXIS PRECISION MEDICINES, INC.
- **STREET 2:** ONE BROADWAY, 16TH FLOOR
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Praxis Precision Medicines, Inc.
- **CENTRAL INDEX KEY:** 0001689548
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 99 HIGH STREET, 30TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02110
- **BUSINESS PHONE:** 617-300-8460

**MAIL ADDRESS:**
- **STREET 1:** 99 HIGH STREET, 30TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02110

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Mastrocola Lauren<br><sub>(Last) (First) (Middle)</sub><br>C/O PRAXIS PRECISION MEDICINES, INC.<br>99 HIGH STREET, 30TH FLOOR<br><sub>(Street)</sub><br>BOSTON, MA 02110<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-11-20 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Principal Accounting Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Praxis Precision Medicines, Inc. [ PRAX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2025-11-20 |  | M |  | 1047 | A | $49.50 | 11488.656 | D |  |
| Common Stock | 2025-11-20 |  | M |  | 508 | A | $83.85 | 11996.656 | D |  |
| Common Stock | 2025-11-20 |  | M |  | 1557 | A | $133.65 | 13553.656 | D |  |
| Common Stock | 2025-11-20 |  | M |  | 2680 | A | $43.37 | 16233.656 | D |  |
| Common Stock | 2025-11-20 |  | M |  | 207 | A | $44.40 | 16440.656 | D |  |
| Common Stock | 2025-11-20 |  | M |  | 2351 | A | $44.40 | 18791.656 | D |  |
| Common Stock | 2025-11-20 |  | M |  | 5250 | A | $56.94 | 24041.656 | D |  |
| Common Stock | 2025-11-20 |  | S |  | 11455 | D | 191.958<sup>(1)</sup> | 12586.656 | D |  |
| Common Stock | 2025-11-20 |  | S |  | 2145 | D | 192.711<sup>(2)</sup> | 10441.656 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | $49.50 | 2025-11-20 |  | M |  |  | 1047 | <sup>(3)</sup> | 2029-09-23 | Common Stock | 1047 | $0.00 | 0 | D |  |
| Stock Option (Right to Buy) | $83.85 | 2025-11-20 |  | M |  |  | 508 | <sup>(4)</sup> | 2030-06-04 | Common Stock | 508 | $0.00 | 0 | D |  |
| Stock Option (Right to Buy) | $133.65 | 2025-11-20 |  | M |  |  | 1557 | <sup>(5)</sup> | 2030-09-13 | Common Stock | 1557 | $0.00 | 0 | D |  |
| Stock Option (Right to Buy) | $43.37 | 2025-11-20 |  | M |  |  | 2680 | <sup>(6)</sup> | 2034-01-12 | Common Stock | 2680 | $0.00 | 9320 | D |  |
| Stock Option (Right to Buy) | $44.40 | 2025-11-20 |  | M |  |  | 207 | 2023-01-12 | 2033-01-12 | Common Stock | 207 | $0.00 | 0 | D |  |
| Stock Option (Right to Buy) | $44.40 | 2025-11-20 |  | M |  |  | 2351 | <sup>(7)</sup> | 2033-01-12 | Common Stock | 2351 | $0.00 | 981 | D |  |
| Stock Option (Right to Buy) | $56.94 | 2025-11-20 |  | M |  |  | 5250 | <sup>(8)</sup> | 2034-07-29 | Common Stock | 5250 | $0.00 | 11376 | D |  |

---

### Footnotes:

(1) The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $191.500 to $192.432. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

(2) The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $192.552 to $193.109. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

(3) This option was fully vested as of January 1, 2023.

(4) This option was fully vested as of May 28, 2024.

(5) This option was fully vested as of September 8, 2024.

(6) The shares underlying this stock option vested as to 50% on January 12, 2024 and the remaining 50% vesting over a four-year period, with 25% of such shares vesting on January 12, 2025 and the remaining vesting in substantially equal monthly installments over the following 36 months, subject to the Reporting Person's continued service through each vesting date.

(7) The shares underlying this stock option vested as to 25% on January 12, 2024 and the remaining shares vest in substantially equal monthly installments over the following 36 months, subject to the Reporting Person's continued service through each vesting date.

(8) The shares underlying this stock option vested as to 7/48ths on July 29, 2024 and the remaining shares vest in substantially equal monthly installments over the following 41 months, subject to the Reporting Person's continued service through each vesting date.

**Remarks:**
The transactions reported in this Form 4 were effected for estate planning purposes.

**Signature:** /s/ Alex Nemiroff, as Attorney-in-Fact  
**Date:** 2025-11-21

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**